Track topics on Twitter Track topics that are important to you
Purpose: to evaluate the immediate effect of automated oxygen titration compared to usual fixed-dose oxygen treatment during exercise in patients with COPD on long-term oxygen treatment.
Methods: The study will be conducted as a double blinded randomized crossover trial with two arms. 40 ambulatory patients with COPD and home oxygen treatment will be included from AHH Hospital's catchment area. The patients will conduct two Endurance Shuttle Walk Tests (ESWT) in a crossover design using an O2matic device to deliver a variable oxygen dosage set at an SpO2-target of 90-94% and an O2-flow of 0 - 15 liters/min and using the patients´ usual fixed-dose oxygen delivery, in a randomized order. In both arms O2matic will monitor pulse rate and SpO2 continuously during the test, but only in the automated oxygen titration arm will O2matic adjust oxygen flow. The patient and the physiotherapist supervising the tests will be blinded to the oxygen dose. Primary outcome is the changes in perceived dyspnea intensity using Borg CR10 scale between walking with automated titration compared to fixed-dose treatment. Secondary outcomes are differences in walking time, the average oxygen consumption between automated oxygen titration and fixed-dose treatment and difference in time spent within acceptable SpO2-interval.
Long-term oxygen treatment (LTOT) at home is essential for patients with COPD and chronic hypoxemia. It is recommended that the given oxygen flow rate should be enough to keep the blood saturation (SpO2) between 90% and 94%. Although the oxygen need increases with activity, there is no consensus on oxygen dosage during activity (BTS-guideline).
The purpose of this study is to evaluate the immediate effect of automated oxygen titration (AOT) compared to usual fixed-dose oxygen treatment (FOT) during exercise in patients with COPD on long-term oxygen treatment.
Method The study will be performed on 40 patients with COPD and on LTOT. An incremental shuttle walk test (ISWT) will be performed to establish the walking speed corresponding to 75% of the estimated peak oxygen consumption. The patients will all use a rollator as walking aid and the oxygen equipment will be placed in the rollator. The patients will after inclusion conduct two Endurance Shuttle Walk Tests (ESWT) with FOT and AOT respectively in a randomized order. One ESWT will be performed using O2matic to deliver a variable oxygen dosage set at an SpO2-target of 90 to 94 % and a O2-flow of 0 - 15 liters/min (AOT). The other ESWT will be performed using the usual fixed-dose oxygen delivery (FOT).
The patients will also conduct two six minutes walking tests (6 MWT) with FOT and AOT in random order in the same way as mentioned above.
Demographic data, including body mass index, and smoking history, will be registered. Use of a rollator, and usual flow of oxygen supplementation will be registered. The score in the CAT- questionnaire (COPD Assessment Test, range of 0-40) will be registered along with the results of the MRC (Medical Research Council, range 1-5).
A lung function test will be performed using Medikro Pro Spirometer. Forced Expiratory Volume in the first second (FEV1) and Forced Vital Capacity (FVC) will be recorded. All lung function measures will be expressed in absolute values and in percent of predicted.
Dyspnea will be registered using Borg Dyspnea Scale CR10 (6). Before, and after completing the 6MWT the patients will be asked to rate their intensity of dyspnea. At the ESWT the patients will rate their intensity of dyspnea before and after completing the test and every minute during the test.
Shuttle Walk Test will be performed using the Incremental Shuttle Walk Test (ISWT) followed by the Endurance Shuttle Walk Test (ESWT) on two different days. ISWT is initially conducted once for familiarization followed by a second test. The patients will be given a rest of 20 minutes between tests and the best result is recorded. The results of ISWT will be used to calculate the walking speed in the ESWT, which will be set at 75% of max and not 85% of max as the intension is to keep the patients walking for more than just 1-3 minutes. The patient is in both tests required to walk around two cones set 9 meters apart (so the final track is 10 meters). In the ESWT the patients are asked to walk as long as possible until they are unable to continue. The time walked in the ESWT will be registered.
The six-minute walking test (6 MWT), assesses the distance walked in metres over six minutes as a sub-maximal test of aerobic capacity/endurance. It requires the patient to walk between cones set 30 meters apart(8).
Walking limitation will be noted. The patients will be asked to report the primary limitation for not being able to walk longer: dyspnea, leg fatigue, pain, discomfort, anxiety or "other reasons".
Oxygen consumption and oxygen saturation (SpO2) will be registered using O2matic, a device which adjusts the oxygen flow to maintain the saturation within a target interval. O2matic is a device, which based on continuous, non-invasive measurement of SpO2 adjusts oxygen flow to the patient within a defined target interval. SpO2-target can be set individually, but in this study will be fixed at 90 to 94 %. If SpO2 falls below 90 % oxygen flow will increase, and if SpO2 increases above 94 % oxygen flow will decrease. The adjustments are done every second based on average SpO2 for the last 15 seconds. In case of low SpO2 (below target or below 85 %), low pulse rate (<45) or high pulse rate (user defined) an alarm will be visible and audible.
Statistical considerations and strength calculation:
The primary outcome is change in the BORG CR10 dyspnea scale. The minimal clinical important difference (MCID) is 1 unit (9) and standard deviation expected to be 2.0. Based on alfa of 0,05 and a power of 80 % a sample of 33 patients is needed to examine if AOT results in improvement in time walked during the ESWT. Due to possible dropout 40 patients will be included in the study. Categorical variables are compared using Chi-Square or Fisher's exact test, as appropriate. Continuous variables are examined for normality and analyzed with either unpaired t-test (in case of normality) or Wilcoxon-Mann-Whitney test (in case of non-normality). The Statistical Package SPSS ver. 22 will be used for all statistical analyses.
The study will take place at Hvidovre Hospital from October 2019 and until all 40 patients are included. Linette Marie Kofod is the principal investigator. The study will be conducted as an interdisciplinary collaboration between the Pulmonary Section and the Department of Physiotherapy, Amager and Hvidovre University Hospital, which have approved the study.
Chronic Obstructive Pulmonary Disease
Fixed-dose compared to variable oxygen flow supplementation during walking
Not yet recruiting
Hvidovre University Hospital
Published on BioPortfolio: 2019-10-16T10:39:19-0400
Oxygen therapy is a cornerstone in treating patients with severe chronic obstructive pulmonary disease. Usually, oxygen supplementation is delivered using constant-flow rates. Varying oxyg...
Hypoxemia is common in acute ischemic stroke and associated with neurological deterioration and mortality. However, the benefit of oxygen therapy is controversial. Severity of stroke may a...
The study aims to compare the efficacy of Nasal High Flow Therapy (NHF) with low-flow oxygen supplementation in improving postoperative intermittent desaturations. If so, this mode of ther...
The primary objective of this study is to test the hypothesis that using high flow nasal oxygen improves ventilation during cardiac implantable electronic device procedures performed with ...
The goal of this clinical research study is to compare high-flow oxygen, low-flow oxygen, high-flow air, and low-flow air in helping to decrease shortness of breath in cancer patients. Res...
Trans-nasal aerosol deposition during distressed breathing is higher than quiet breathing, and decreases as administered gas flow increases. We hypothesize that inhaled dose is related to the ratio of...
The objective of this study was to evaluate the effect of two different doses of vitamin D on the expression of T regulatory cells (Treg) in premature infants. A double blinded randomized controlled t...
To evaluate the clinical impact of biological uncertainties in small field proton therapy due to the assumption of using a constant relative biological effectiveness (RBE) value of 1.1 (RBE-fixed) com...
A novel two-stage fluidized-bed/fixed-bed catalytic system was developed for the treatment of benzaldehyde residue. The effects of reaction temperature, oxygen concentration, space velocity on the pur...
Four-factor prothrombin complex concentrate (4F-PCC) has emerged as the preferred option for emergent reversal of vitamin K antagonists (VKAs); however, the optimal dosing strategy is unknown. Althoug...
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
A treatment schedule in which the total dose of radiation is divided into large doses.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...